血浆血栓调节蛋白作为肝细胞癌门静脉癌栓生物标志物的潜力。

The potential of plasma thrombomodulin as a biomarker of portal vein tumor thrombus in hepatocellular carcinoma.

作者信息

Zhou J, Tang Z Y, Fan J, Wu Z Q, Ji Y, Ye S L

机构信息

Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, PR China.

出版信息

J Cancer Res Clin Oncol. 2001 Sep;127(9):559-64. doi: 10.1007/s004320100237.

DOI:10.1007/s004320100237

PMID:11570577

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12164799/

Abstract

PURPOSE

To study the relationship between thrombomodulin (TM) plasma levels and the formation of portal vein tumor thrombus (PVTT) in patients with hepatocellular carcinoma (HCC).

METHODS

Pre- and-postoperative plasma TM levels of 45 patients with HCC and six patients with benign liver-occupying lesion were measured by enzyme-linked immunosorbent assay (ELISA), and the expression of TM in human HCC tissues was determined by immunohistochemistry assay.

RESULTS

The preoperative plasma TM level of patients with HCC (10.2+/-5.7 ng/ml) was significantly higher than that of those patients with benign liver-occupying lesion (6.1+/-2.2 ng/ml) and that of normal controls (5.7+/-1.0 ng/ml), respectively (P<0.05). The postoperative TM level of 40 patients with HCC whose tumors had been removed decreased significantly than the preoperative TM level (10.8+/-5.3 ng/ml versus 7.6+/-4.2 ng/ ml, P < 0.05), whereas there was no significant difference between the preoperative and postoperative TM level of six patients with benign liver-occupying lesion (6.1+/-2.2 ng/ml versus 5.9+/-1.8 ng/ml, P>0.05). The preoperative plasma TM level of patients with single HCC (11.5+/-5.9 ng/ml) or no PVTT (11.4+/-5.6 ng/ml) was significantly higher than that of those patients with multiple HCC (8.1+/-4.6 ng/ml) or PVTT (6.9+/-4.5 ng/ ml), respectively (P<0.05). The preoperative plasma TM level of the patients with HCC tissue that stained positive for TM was significantly higher than those with tissue that stained negative for TM (12.2+/-6.5 ng/ ml versus 8.7+/-4.6 ng/ml, P<0.05). The postoperative plasma TM level showed no difference between the patients with HCC tissue stained positive and negative for TM (8.3+/-4.1 ng/ml versus 7.6+/-4.4 ng/ml, P>0.05). There was also no significant difference between the plasma TM level and other clinicopathological futures.

CONCLUSIONS

Plasma TM increases in patients with HCC and can be a biomarker of the formation of PVTT.

摘要

目的

研究肝细胞癌（HCC）患者血浆血栓调节蛋白（TM）水平与门静脉癌栓（PVTT）形成之间的关系。

方法

采用酶联免疫吸附测定（ELISA）法检测45例HCC患者及6例肝脏良性占位性病变患者术前和术后的血浆TM水平，采用免疫组织化学法检测人HCC组织中TM的表达。

结果

HCC患者术前血浆TM水平（10.2±5.7 ng/ml）分别显著高于肝脏良性占位性病变患者（6.1±2.2 ng/ml）和正常对照组（5.7±1.0 ng/ml）（P<0.05）。40例肿瘤已切除的HCC患者术后TM水平较术前显著降低（10.8±5.3 ng/ml对7.6±4.2 ng/ml，P<0.05），而6例肝脏良性占位性病变患者术前和术后TM水平无显著差异（6.1±2.2 ng/ml对5.9±1.8 ng/ml，P>0.05）。单发HCC患者（11.5±5.9 ng/ml）或无PVTT患者（11.4±5.6 ng/ml）术前血浆TM水平分别显著高于多发HCC患者（8.1±4.6 ng/ml）或有PVTT患者（6.9±4.5 ng/ml）（P<0.05）。TM染色阳性的HCC组织患者术前血浆TM水平显著高于TM染色阴性的患者（12.2±6.5 ng/ml对8.7±4.6 ng/ml，P<0.05）。TM染色阳性和阴性的HCC组织患者术后血浆TM水平无差异（8.3±4.1 ng/ml对7.6±4.4 ng/ml，P>0.05）。血浆TM水平与其他临床病理特征之间也无显著差异。